Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665101 | 0.87 | REN (0.36) | RENSMN1; SMN2HTTHSD17B10TLR8 | |
| SCHEMBL8037049 | 0.80 | SMN1; SMN2 (0.37) | RENSMN1; SMN2HTTHSD17B10TLR8 | |
| SCHEMBL4686191 | 0.77 | REN (0.34) | RENCYP3A4ALDH1A1 | |
| SCHEMBL91265 | 0.77 | REN (0.41) | RENSMN1; SMN2HTTHSD17B10TLR8 | |
| SCHEMBL78902 | 0.76 | LMNA (0.41) | RENSMN1; SMN2HTTHSD17B10TLR8 | |
| SCHEMBL20642297 | 0.75 | LMNA (0.32) | P2RX3P2RX2 | |
| SCHEMBL662543 | 0.75 | ALDH1A1 (0.35) | RENSMN1; SMN2HTTHSD17B10TLR8 | |
| SCHEMBL13154801 | 0.72 | CYP2C8 (0.39) | RENSMN1; SMN2TRPV1CYP3A4 | |
| SCHEMBL24650722 | 0.72 | HCAR3 (0.43) | SMN1; SMN2HSD17B10P2RX3P2RX2CYP3A4 | |
| SCHEMBL662621 | 0.71 | REN (0.35) | RENSMN1; SMN2HTTHSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249163-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-09-30 | — | — | US | disclosed |
| US-20100249163-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249163-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885SMN1; SMN2 4691/4885HTT 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.